BRIEF published on 06/27/2024 at 18:20, 1 year 7 months ago Dermapharm Holding SE : l'Assemblée générale annuelle décide de distribuer un dividende de 0,88 EUR par action Dividende Assemblée Générale Annuelle Perspectives Financières Dermapharm
BRIEF published on 06/27/2024 at 18:20, 1 year 7 months ago Dermapharm Holding SE: Annual General Meeting Resolves Dividend Distribution of EUR 0.88 Per Share Annual General Meeting Dividend Financial Outlook Dermapharm
PRESS RELEASE published on 06/27/2024 at 18:15, 1 year 7 months ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share Dermapharm Holding SE's Annual General Meeting approves EUR 0.88 per share dividend distribution for 2024. Board actions confirmed. Outlook and acquisitions strategies highlighted Annual General Meeting Acquisitions Outlook Dividend Distribution Dermapharm Holding SE
BRIEF published on 05/15/2024 at 07:35, 1 year 8 months ago Dermapharm Holding SE annonce une baisse de son chiffre d'affaires au premier trimestre 2024 dans un contexte de forte croissance des produits pharmaceutiques de marque Résultats Financiers Croissance Organique Résilience Du Marché Produits De Santé Produits Pharmaceutiques De Marque
BRIEF published on 05/15/2024 at 07:35, 1 year 8 months ago Dermapharm Holding SE Reports Decline in Q1 2024 Revenue Amidst Strong Branded Pharmaceuticals Growth Financial Results Organic Growth Market Resilience Healthcare Products Branded Pharmaceuticals
PRESS RELEASE published on 05/15/2024 at 07:30, 1 year 8 months ago Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy Dermapharm Holding SE reports strong organic growth in core markets with resilient corporate strategy in Q1 2024 Organic Growth Q1 2024 Core Markets Dermapharm Holding SE Resilient Strategy
BRIEF published on 03/28/2024 at 07:35, 1 year 10 months ago Dermapharm Holding SE répond à toutes les attentes dans un contexte économique difficile Rapport Annuel 2023 Défis Économiques Dermapharm Holding SE Industrie Pharmaceutique Attentes De Croissance
BRIEF published on 03/28/2024 at 07:35, 1 year 10 months ago Dermapharm Holding SE Meets All Expectations in Challenging Economic Climate Pharmaceutical Industry Annual Report 2023 Economic Challenges Dermapharm Holding SE Growth Expectations
PRESS RELEASE published on 03/28/2024 at 07:30, 1 year 10 months ago Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges Dermapharm Holding SE fulfils all expectations in 2023 despite macroeconomic challenges, with revenue up by 10.8% to EUR 1,135.4 million and adjusted EBITDA margin at 27.3% Pharmaceutical Industry Revenue Growth EBITDA Margin Annual Report Dermapharm Holding SE
BRIEF published on 03/14/2024 at 07:35, 1 year 10 months ago Dermapharm Holding SE atteint l'extrémité supérieure de sa fourchette d'orientation malgré les défis Résultats Financiers Hausse Des Revenus Médicaments Dermapharm Holding SE Produits De Santé
Published on 01/30/2026 at 02:15, 1 hour 4 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 3 hours 19 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 4 hours 19 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 8 hours 34 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 9 hours 19 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/30/2026 at 00:07, 3 hours 11 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 6 hours 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 6 hours 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/29/2026 at 20:59, 6 hours 19 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 6 hours 21 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/29/2026 at 18:30, 8 hours 49 minutes ago ALPOU - Groupe POULAILLON chiffre d'affaires trimestriel T1 2025-2026 et Focus sur les activités
Published on 01/29/2026 at 18:00, 9 hours 19 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 18:00, 9 hours 19 minutes ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES CONSOLIDE ANNUEL 2025 : +2%
Published on 01/29/2026 at 17:45, 9 hours 34 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
